

LEGAL Wilmington, Delaware 19898 92 OCT 27 PM 1: 48



21

SEHQ -92-123 INIT SP20010594

A

No CBI

October 15, 1992

Certified Mail
Return Receipt Requested

Document Processing Center (TS-790)
Office of Pollution Prevention and Toxics
Environmental Protection Agency
401 M Street., S.W.
Washington, D.C. 20460
Atm: Section 8(e) Coordinator (CAP Agreement)

Dear Coordinator:

8ECAP-0025

On behalf of the Regulatee and pursuant to Unit II B.1.b. and Unit II C of the 6/28/91CAP Agreement, E.I. Du Pont de Nemours and Co. hereby submits (in triplicate) the attached studies. Submission of this information is voluntary and is occasioned by unilateral changes in EPA's standard as to what EPA now considers as reportable information. Regulatee's submission of information is made solely in response to the new EPA §8(e) reporting standards and is not an admission: (1) of TSCA violation or liability; (2) that Regulatee's activities with the study compounds reasonably support a conclusion of substantial health or environmental risk or (3) that the studies themselves reasonably support a conclusion of substantial health or environmental risk.

The "Reporting Guide" creates new TSCA 8(e) reporting criteria which were not previously announced by EPA in its 1978 Statement of Interpretation and Enforcement Policy, 43 Fed Reg 11110 (March 16, 1978). The "Reporting Guide states criteria which expands upon and conflicts with the 1978 Statement of Interpretation. Absent amendment of the Statement of Interpretation, the informal issuance of the "Reporting Guide" raises significant due processes issues and clouds the appropriate reporting standard by which regulated persons can assure TSCA Section 8(e) compliance.

Mark H. Christman

Counsel

Legal D-7158 1007 Market Street

Wilmington, DE 19898

(302) 774-6443

CPKIP I

Better Things for Better Living

ATTACHMENT 1

Submission of information is made under the 6/28/91 CAP Agreement, Unit II. This submission is made voluntarily and is occasioned by recent changes in EPA's TSCA §8(e) reporting standard; such changes made, for the first time in 1991 and 1992 without prior notice and in violation of Regulatee's constitutional due process rights. Regulatee's submission of information under this changed standard is not a waiver of its due process rights; an admission of TSCA violation or liability, or an admission that Regulatee's activities with the study compounds reasonably support a conclusion of substantial risk to health or to the environment. Regulatee has historically relied in good faith upon the 1978 Statement of Interpretation and Enforcement Policy criteria for determining whether study information is reportable under TSCA §8(e), 43 Fed Reg 11110 (March 16, 1978). EPA has not, to date, amended this Statement of Interpretation.

After CAP registration, EPA provided the Regulatee the June 1, 1991 "TSCA Section 8(e) Reporting Guide". This "Guide" has been further amended by EPA, EPA letter, April 10, 1992. EPA has not indicated that the "Reporting Guide" or the April 1992 amendment supersedes the 1978 Statement of Interpretation. The "Reporting Guide" and April 1992 amendment substantively lowers the Statement of Interpretation 's TSCA §8(e) reporting standard². This is particularly troublesome as the "Reporting Guide" states criteria, applied retroactively, which expands upon and conflicts with the Statement of Interpretation.³ Absent amendment of the Statement of Interpretation, the informal issuance of the "Reporting Guide" and the April 1992 amendment clouds the appropriate standard by which regulated persons must assess information for purposes of TSCA §8(e).

²In sharp contrast to the Agency's 1977 and 1978 actions to soliciting public comment on the proposed and final §8(e) Policy, EPA has unilaterally pronounced §8(e) substantive reporting criteria in the 1991 Section 8(e) Guide without public notice and comment, See 42 Fed Reg 45362 (9/9/77), "Notification of Substantial Risk under Section 8(e): Proposed Guidance".

³A comparison of the 1978 Statement of Interpretation and the 1992 "Reporting Guide" is a appended.

Throughout the CAP, EPA has mischaracterized the 1991 guidance as reflecting "longstanding" EPA policy concerning the standards by which toxicity information should be reviewed for purposes of §8(e) compliance. Regulatee recognizes that experience with the 1978 Statement of Interpretation may cause a review of its criteri. Regulatee supports and has no objection to the Agency's amending reporting criteria provided that such amendment is not applied to the regulated community in an unfair way. However, with the unilateral announcement of the CAP under the auspices of an OCM enforcement proceeding, EPA has wrought a terrific unfairness since much of the criteria EPA has espoused in the June 1991 Reporting Guide and in the Agency's April 2, 1992 amendment is new criteria which does not exist in the 1978 Statement of Interpretation and Enforcement Policy.

The following examples of new criteria contained in the "Reporting Guide" that is not contained in the <u>Statement of Interpretation</u> follow:

- o even though EPA expressly disclaims each "status report" as being preliminary evaluations that should <u>not</u> be regarded as final EPA policy or intent⁴, the "Reporting Guide" gives the "status reports" great weight as "sound and adequate basis" from which to determine mandatory reporting obligations. ("Guide" at page 20).
- o the "Reporting Guide" contains a matrix that establishes new numerical reporting "cutoff" concentrations for acute lethality information ("Guide" at p. 31). Neither this matrix nor the cutoff values therein are contained in the <u>Statement of Interpretation</u>. The regulated community was not made aware of these cutoff values prior to issuance of the "Reporting Guide" in June, 1991.
- othe "Reporting Guide" states new specific definitional criteria with which the Agency, for the first time, defines as 'distinguishable neurotoxicological effects'; such criteria/guidance not expressed in the 1978 Statement of Interpretation. 5:

othe "Reporting Guide" provides new review/ reporting criteria for irritation and sensitization studies; such criteria not previously found in the 1978 <u>Statement of Interpretation/Enforcement Policy</u>.

othe "Reporting Guide" publicizes certain EPA Q/A criteria issued to the Monsanto Co. in 1989 which are not in the <u>Statement of Interpretation</u>; have never been published in the <u>Federal Register</u> or distributed by the EPA to the Regulatee. Such Q/A establishes new reporting criteria not previously found in the 1978 <u>Statement of Interpretation/Enforcement Policy</u>.

⁴The 'status reports' address the significance, if any, of particular information reported to the Agency, rather than stating EPA's interpretation of §8(e) reporting criteria. In the infrequent instances in which the status reports contain discussion of reportability, the analysis is invariably quite limited, without substantial supporting scientific or legal rationale.

⁵ See, e.g., 10/2/91 letter from Du Pont to EPA regarding the definition of 'serious and prolonged effects' as this term may relate to transient anesthetic effects observed at lethal levels; 10/1/91 letter from the American Petroleum Institute to EPA regarding clarification of the <u>Reporting Guide</u> criteria.

In discharging its responsibilities, an administrative agency must give the regulated community fair and adequate warning to as what constitutes noncompliance for which penalties may be assessed.

Among the myriad applications of the due process clause is the fundamental principle that statutes and regulations which purport to govern conduct must give an adequate warning of what they command or forbid.... Even a regulation which governs purely economic or commercial activities, if its violation can engender penalties, must be so framed as to provide a constitutionally adequate warning to those whose activities are governed.

Diebold, Inc. v. Marshall, 585 F.2d 1327, 1335-36 (D.C. Cir. 1978). See also, Rollins Environemntal Services (NJ) Inc. v. U.S. Environmental Protection Agency, 937 F. 2d 649 (D.C. Cir. 1991).

While neither the are rules, This principle has been applied to hold that agency 'clarification', such as the <u>Statement of Interpretation</u>, the "Reporting Guide" nor the April 1992 amendments will not applied retroactively.

...a federal court will not retroactively apply an unforeseeable interpretation of an administrative regulation to the detriment of a regulated party on the theory that the post hoc interpretation asserted by the Agency is generally consistent with the policies underlying the Agency's regulatory program, when the semantic meaning of the regulations, as previously drafted and construed by the appropriate agency, does not support the interpretation which that agency urges upon the court.

Standard Oil Co. v. Federal Energy Administration, 453 F. Supp. 203, 240 (N.D. Ohio 1978), aff'd sub nom. Standard Oil Co. v. Department of Energy, 596 F.2d 1029 (Em. App. 1978):

The 1978 Statement of Interpretation does not provide adequate notice of, and indeed conflicts with, the Agency's current position at §8(e) requires reporting of all 'positive' toxicological findings without regard to an assessment of their relevance to human health. In accordance with the statute, EPA's 1978 Statement of Interpretation requires the regulated community to use scientific judgment to evaluate the significance of toxicological findings and to determining whether they reasonably support a conclusion of a substantial risk. Part V of the Statement of Interpretation urges persons to consider "the fact or probability" of an effect's occurrence. Similarly, the 1978 Statement of Interpretation stresses that an animal study is reportable only when "it contains reliable evidence ascribing the effect to the chemical." 43 Fed Reg. at 11112. Moreover, EPA's Statement of Interpretation defines the substantiality of risk as a function of both the seriousness of the effect and the probability of its occurrence. 43 Fed Reg 11110 (1978). Earlier Agency interpretation also emphasized the "substantial" nature of a §8(e) determination. See 42 Fed Reg 45362, 45363

(1977). [Section 8(e) findings require "extraordinary exposure to a chemical substance...which critically imperil human health or the environment"].

The recently issued "Reporting Guide" and April 1992 Amendment guidance requires reporting beyond and inconsistent with that required by the <u>Statement of Interpretation</u>. Given the statute and the <u>Statement of Interpretation</u>'s explicit focus on substantial human or environmental risk, whether a substance poses a "substantial risk" of injury requires the application of scientific judgment to the available data on a case-by-case basis.

If an overall weight-of-evidence analysis indicates that this classification is unwarranted, reporting should be unnecessary under §8(e) because the available data will not "reasonably support the conclusion" that the chemical presents a <u>substantial</u> risk of serious adverse consequences to human health.

Neither the legislative history of §8(e) nor the plain meaning of the statute support EPA's recent lowering of the reporting threshold that TSCA §8(e) was intended to be a sweeping information gathering mechanism. In introducing the new version of the toxic substances legislation, Representative Eckhart included for the record discussion of the specific changes from the version of H. R. 10318 reported by the Consumer Protection and Finance Subcommittee in December 1975. One of these changes was to modify the standard for reporting under §8(e). The standard in the House version was changed from "causes or contributes to an unreasonable risk" to "causes or significantly contributes to a substantial risk". This particular change was one of several made in TSCA §8 to avoid placing an undue burden on the regulated community. The final changes to focus the scope of Section 8(e) were made in the version reported by the Conference Committee.

The word "substantial" means "considerable in importance, value, degree, amount or extent". Therefore, as generally understood, a "substantial risk" is one which will affect a considerable number of people or portion of the environment, will cause serious injury and is based on reasonably sound scientific analysis or data. Support for the interpretation can be found in a similar provision in the Consumer Product Safety Act. Section 15 of the CPSA defines a "substantial product hazard" to be:

"a product defect which because of the pattern of defect, the number of defective products distributed in commerce, the severity of the risk, or otherwise, creates a substantial risk of injury to the public." Similarly, EPA has interpreted the word 'substantial' as a quantitative measurement. Thus, a 'substantial risk' is a risk that can be quantified, See, 56 Fed Reg 32292, 32297 (7/15/91). Finally, since information pertinent to the exposure of humans or the environment to chemical substances or mixtures may be obtained by EPA through Sections 8(a) and 8(d) regardless of the degree of potential risk, §8(e) has specialized function. Consequently, information subject to §8(e) reporting should be of a type which would lead a reasonable man to conclude that some type action was required immediately to prevent injury to health or the environment.

Attachment

Comparison:

Reporting triggers found in the 1978 "Statement of Interpretation/ Enforcement Policy", 43 Fed Reg 11110 (3/16/78) and the June 1991 Section 8(e) Guide.

TEST TYPE	1978 POLICY CRITERIA EXIST?	New 1991 GUIDE CRITERIA EXIST?
ACUTE LETHALITY		
Oral Dermal Inhalation (Vapors) aerosol dusts/ particles	N} N} }6 N} N}	Y} Y} Y} Y}
SKIN IRRITATION	N	Y ⁸
SKIN SENSITIZATION (ANIM	ALS) N	Y ⁹
EYE IRRITATION	N	Y ¹⁰
SUBCHRONIC (ORAL/DERMAL/INHALATION	i) N	Y ¹¹
REPRODUCTION STUDY	N	Y ¹²
DEVELOPMENTAL TOX	Y ¹³	Y ¹⁴

⁶⁴³ Fed Reg at 11114, comment 14:

[&]quot;This policy statements directs the reporitng of specifiec effects when unknown to the Administrator. Many routine tests are based on a knowledge of toxicity associated with a chemicalL unknown effects occurring during such a range test may have to be reported if they are those of concern tot he Agency and if the information meets the criteria set forth in Parts V and VII."

⁷Guide at pp.22, 29-31.

⁸Guide at pp-34-36.

⁹Guide at pp-34-36.

¹⁰ Guide at pp-34-36.

¹¹ Guide at pp-22; 36-37.

¹²Guide at pp-22

¹³⁴³ Fed Reg at 11112

[&]quot;Birth Defects" listed.

¹⁴Guide at pp-22

NEUROTOXICITY	N	Y ¹⁵
CARCINOGENICITY	Y ¹⁶	Y ¹⁷
MUTAGENICITY		
In Vitro In Vivo	Y} ¹⁸ Y}	Y} ¹⁹ Y}
ENVIRONMENTAL		
Bioaccumulation Bioconcentration Oct/water Part. Coeff.	Y} Y} ²⁰ Y}	N N N
Acute Fish	N	N
Acute Daphnia	N	N
Subchronic Fish	N	N
Subchronic Daphnia	N .	N
Chronic Fish	N	N
AVIAN		
Acute	N Si	N
Reproductive Reproductive	N N	N
remoucuuve	N	N

^{15 &}lt;u>Guide</u> at pp-23; 33-34. 1643 <u>Fed Reg</u> at 11112 "Cancer" listed

¹⁷ Guide at pp-21.

¹⁸⁴³ Fed Reg at 11112; 11115 at Comment 15

"Mutagenicity" listed/ in vivo vs invitro discussed; discussion of "Ames test".

¹⁹Guide at pp-23. ²⁰43 Fed Reg at 11112; 11115 at Comment 16.

CAS #: 56-23-5; 67-66-3; 79-01-6; 127-18-4; 71-55-6; 79-34-5; 79-00-5

Chem: Carbon tetrachloride; chloroform; trichloroethylene; tetrachloroethylene; 1,1,1-trichloroethane; 1,1,2-2-chloroethane; 1,1,2-2

ethane; 1,1,2-trichloroethane.

Title: Comparative Hepatotoxicity of Seven Halogenated

hycrocarbons.

Date: Not dated

Summary of Effects: "Significant" sleeping time with all compounds at sublethal dose; kidney and liver damage in animcals at high dose.

BEST COPY AVAILABLE

Comparative Hepatotoxicity of Seven Halogenated Hydrocarbons. G. L. Plaa*, E. A. Evans*, and C. H. Hine. Dept. of Pharmacology and Expti. Therapeutics, Univ. of California School of Medicine, San Francisco.

The hepatotoxic potency of a series of aliphatic halogenated hydrocarbons of low molecular weight was evaluated by measurement of prolongation of pentobarbital anesthesia. Pentobarbital was given to mice in a single intraperitoneal dose of 45 mg/kg, 24 hours after a single hydrocarbon injection. In 270 control (pentobarbital only) observations, the mean sleeping time was 1.5 ± 4.1 minutes; only 22% of the controls actually lost their righting reflex. In the experimental animals, a sleeping time greater than 10 minutes was considered significant. It w...s possible to produce a significant prolongation of sleeping time with all the compounds at a sublethal dose. The hepatotoxic ED50 in moles per kilo was 5.5 x 10-4 for carbon tetrachloride, 1.8 x 10-3 for chloroform, 1.1 x 10-2 for trichloroethylene, 2.8 x 10-2 for tetrachloroethylene. The toxicity of 1, 1, 1-trichloroethane; 1, 1, 2, 2-tetrachloroethane; and 1, 1, 2trichloroethane increased in that order, and doses which produced significant increase in sleeping time in half the animals also produced death. At necropsy, livers of animals given lower doses were grossly and microscopically normal; at higher doses there was increasing discoloration and friability. Microscopically, varying degrees of central necrosis were seen, correlating well with the observed prolongation of sleeping time. Most animals receiving chloroform and trichloroethane showed renal tubular necrosis, even at doses which did not significantly prolong the sleeping time; these changes were not apparent grossly. This study JWW was supported in part by a grant from E. I. DuPont de Nemours Co.



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

WASHINGTON, D.C. 20460

Mark H. Christman Counsel E. I. Du Pont De Nemours and Company Legal D-7010-1 1007 Market Street Wilmington, Delaware 19898

OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES

APR 1 8 1995

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Court 1 Act (TSCA). For your reference, copies of the first page(s) of your submission(s) a senctosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".

all TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 1110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

Terry R. O'Bryan Risk Analysis Branch

Enclosure

12385A

Recycled/Recyclable
Printed with Soy/Canola Ink on paper that
contains at least 50% recycled fiber

Triage of 8(e) Submissions

Date sent to triage:		<u>2 0</u> 1995	NO	N-CAP	САР	
Submission number:	12385 F		TSC	CA Inventory:	Y N	D
Study type (circle app	propriate):			***************************************		
Group 1 - Dick Cleme	ents (1 copy tota	al)			•	
ECO	AQUATO					
Group 2 - Ernie Falke	e (1 copy total)					
ATOX	SBTOX	SEN	w/NEUR			
Group 3 - Elizabeth N	Margosches (1 c	opy each)			•	
STOX	стох	EPI	RTOX	GTOX		
STOX/ONCO	CTOX/ONCO	IMMUNO	CYTO	NEUR		
Notes: THIS IS THE ORIGINAL	NAL 8(e) SUBM	ISSION; PLEA	ASE REFILE AI	FTER TRIAGE D	ATABASE EI	NTRY
entire documen	t: 6)1 2	For Contract	or Use Only	pages	nas	
Notes: Contractor revie	PO	R	Date:	3/2/9	5	

2,
¥
_
7
-
>-
~
-
Z,
ш
r+1
**
₹
≥
₩.
\Box
-
J
z
=
×
C
Č
~
-
Œ
Ö
×
≤
~
E
5
2
-
<
U
ŏ
$\overline{}$
_

CECATS DATA: Submission # BEHQ. TYPE: INT. SUPP FLWP SUBMITTER NAME.	A. 1092 - 12385 SEO.H A.E. E. I. Dupont do Nemans and Com	5 sto.A.	INFORMATION REQUESTED: FLWP DATE: 0501 NO INFO REQUESTED 0502 INFO REQUESTED (TECH) 0503 INFO REQUESTED (VOL ACTIONS) 0504 INFO REQUESTED (VEPORTING RATIONALE) DISPOSITION: 0609 REFER TO CHEMICAL SCREENING	VP DATE: TIONS) TING RATIONALE) EENING	MATCH ACTION RIPOS COME NO ACTION RIPOS COME NOTIFICATION OF COME LABEL ANSIDE CALLA COME APPAUSE DISCOME COME CONFIDENTIAL	YOU LINTARY ACTIONS: DOOD NO ACTION REPORTED DOOD STUDIES PLANNEDAINDER WAY DOOD LARELANSDS CHANGES DOOD PROCESSAIANDEING CHANGES DOOD APPAUSE DISCONTINUED DOOT PRODUCTION DISCONTINUED DOOT PRODUCTION DISCONTINUED	44 110 H. K. D.	·
SUB. DATE:	0 15 9a or	OTS DATE 10 37/92	92 CSRAD DATE 02/13/95	2/13/95	1			
CHEMICAL NAME	·		ðl	56-23-5	9-55-12	,		i
				67-66-3	- N - 34-31-	19-34-5		
				29-01-6	: =			
HAYT NOTTANGOOM	TYPE	P F C INFOR	NFORMATION TYPE	127 - 18-4 N	INFORMATION TYPE:	ங்	P F C	ļ
0201 ONCO 0200 ONCO 0203 CELL T	ONCO (HUMAN) ONCO (ANIMAL) CELL TRANS (IN VITRO) MITTA (IN VITRO)		EPICLIN HUMAN EXPOS (PROD CONTAM) HUMAN EXPOS (ACCIDENTAL) HUMAN EXPOS (MONITORING)	01 02 04 01 02 04 01 02 04 01 02 04	0242 IMMUNO (ANIMAL) 0242 IMMUNO (HUMAN) 0243 CHEM/PHYS PROP 0244 CLASTO (IN VITRO)	ANIMAL) HUMAN) S PROP N VITRO)	01 02 04 01 02 04 01 02 04 01 02 04 01 02 04	
	MUTA (IN VIVO) REPRO/IERATO (HUMAN) REPRO/IERATO (ANIMAL) NEURO (HUMAN) NEURO (ANIMAL)		ECO/AQUA TOX ENV. OCCCREL/FATE EMER INCI OF ENV CONTAKI RESPONSE REQEST DELAY PROD/COMP/CHEM ID	5		HUMAN) REPAIR PROC	01 02 04 01 02 04 01 02 04 01 02 04 01 02 04	
^	ACUTE TOX. (HUMAN) CHR. TOX. (HUMAN) ACUTE TOX. (ANIMAL) SUB ACUTE TOX (ANIMAL) SUB CHRONIC TOX (ANIMAL) CHRONIC TOX (ANIMAL)	01 02 04 0225 01 02 04 0226 01 02 04 0227 01 02 04 0228 01 02 04 0239	REPORTING KALIONALE CONFIDENTIAL ALLERG (HUMAN) ALLERG (ANIMAL) METABIPHARMACO (ANIMAL) METABIPHARMACO (HUMAN)					
TRIAGE DATA	NON-CBI INVENTORY	ONGOING REVIEW	SPECIES TOXICOLOGIC	TOXICOLOGICAL CONCERN:	<u>asn</u>	PRODUCTION		ēt.
CAS 5R	YES	YES (DROP/REFER) NO (CONTINUE)	MED			•	A.	
	IN IS RMINE	REFR						
(Jedhan)			No Locassigned	ssigned				

NO LOC ASSIGNED

CARBON TETRACHLORIDE: HEPATOTOXIC POTENCY WAS EVALUATED IN MICE (NUMBER, SEX, AND STRAIN NOT INDICATED) BY MEASUREMENT OF PENTOBARBITAL ANAESTHESIA (I.P. DOSE GIVEN 24 HOURS AFTER TEST COMPOUND INJECTION). NO LEVEL OF CONCERN WAS ASSIGNED TO THIS INJECTION STUDY. THE HEPATOTOXIC ED50 (TO CAUSE SLEEPING TIME INCREASE OF GREATER THAN 10 MINUTES) WAS 5.5 X 10-4 MOLES/KG (66 MG/KG). THE ED50 DOSE ALSO PRODUCED DEATH (INCIDENCE NOT GIVEN). MICROSCOPICALLY, THE DEGREE OF CENTRAL HEPATIC NECROSIS CORRELATED WELL WITH PROLONGATION OF SLEEPING TIME (DOSE-RESPONSE DATA NOT GIVEN).

CHLOROFORM: HEPATOTOXIC POTENCY WAS EVALUATED IN MICE (NUMBER, SEX, STRAIN NOT INDICATED) BY MEASUREMENT OF PENTOBARBITAL ANAESTHESIA (I.P. GIVEN DOSE 24 HOURS AFTER TEST COMPOUND INJECTION). NO LEVEL OF CONCERN WAS ASSIGNED TO THIS INJECTION STUDY. THE HEPATOTOXIC ED50 (TO CAUSE SLEEPING TIME INCREASE OF GREATER THAN 10 MINUTES) WAS 1.8 X 10-3 MOLES/KG (215 MG/KG). THE ED50 DOSE ALSO PRODUCED DEATH (INCIDENCE NOT GIVEN) AND RENAL TUBULAR NECROSIS. MICROSCOPICALLY, THE DEGREE OF CENTRAL HEPATIC NECROSIS CORRELATED WELL WITH PROLONGATION OF SLEEPING TIME (DOSE-RESPONSE DATA NOT GIVEN).

TRICHLOROETHYLENE: HEPATOTOXIC POTENCY WAS EVALUATED IN MICE (NUMBER, SEX, AND STRAIN NOT INDICATED) BY MEASUREMENT OF PENTOBARBITAL ANAESTHESIA (I.P. DOSE GIVEN 24 HOURS AFTER TEST COMPOUND INJECTION). NO LEVEL OF CONCERN WAS ASSIGNED TO THIS INJECTION STUDY. THE HEPATOTOXIC ED50 (TO CAUSE SLEEPING TIME INCREASE OF GREATER THAN 10 MINUTES) WAS 1.1 X 10-2 MOLES/KG (1445 MG/KG). THE ED50 DOSE ALSO PRODUCED DEATH (INCIDENCE NOT GIVEN) AND RENAL TUBULAR NECROSIS. MICROSCOPICALLY, THE DEGREE OF CENTRAL HEPATIC NECROSIS CORRELATED WELL WITH PROLONGATION OF SLEEPING TIME (DOSE-RESPONSE DATA NOT GIVEN).

TETRACHLOROETHYLENE: HEPATOTOXIC POTENCY WAS EVALUATED IN MICE (NUMBER, SEX, AND STRAIN NOT INDICATED) BY MEASUREMENT OF PENTOBARBITAL ANAESTHESIA (I.P. DOSE GIVEN 24 HOURS AFTER TEST COMPOUND INJECTION). NO LEVEL OF CONCERN WAS ASSIGNED TO THIS INJECTION STUDY. THE HEPATOTOXIC ED50 (TO CAUSE SLEEPING TIME INCREASE OF GREATER THAN 10 MINUTES) WAS 2.8 X 10-2 MOLES/KG (4643 MG/KG). THE ED50 DOSE ALSO PRODUCED DEATH (INCIDENCE NOT GIVEN). MICROSCOPICALLY, THE DEGREE OF CENTRAL HEPATIC NECROSIS CORRELATED

WELL WITH PROLONGATION OF SLEEPING TIME (DOSE-RESPONSE DATA NOT GIVEN).

- 1,1,1-TRICHLOROETHANE: HEPATOTOXIC POTENCY WAS EVALUATED IN MICE (NUMBER, SEX, AND STRAIN NOT INDICATED) BY MEASUREMENT OF PENTOBARBITAL ANAESTHESIA (I.P. DOSE GIVEN 24 HOURS AFTER TEST COMPOUND INJECTION). NO LEVEL OF CONCERN WAS ASSIGNED TO THIS INJECTION STUDY. THE HEPATOTOXIC ED50 (TO CAUSE SLEEPING TIME INCREASE OF GREATER THAN 10 MINUTES) WAS NOT REPORTED. THE ED50 DOSE ALSO PRODUCED DEATH (INCIDENCE NOT GIVEN). MICROSCOPICALLY, THE DEGREE OF CENTRAL HEPATIC NECROSIS CORRELATED WELL WITH PROLONGATION OF SLEEPING TIME (DOSE-RESPONSE DATA NOT GIVEN).
- 1,1,2-2-TETRACHLOROETHANE: HEPATOTOXIC POTENCY WAS EVALUATED IN MICE (NUMBER, SEX, AND STRAIN NOT INDICATED) BY MEASUREMENT OF PENTOBARBITAL ANAESTHESIA (I.P. DOSE GIVEN 24 HOURS AFTER TEST COMPOUND INJECTION). NO LEVEL OF CONCERN WAS ASSIGNED TO THIS INJECTION STUDY. THE HEPATOTOXIC ED50 (TO CAUSE SLEEPING TIME INCREASE OF GREATER THAN 10 MINUTES) WAS NOT REPORTED. THE ED50 DOSE ALSO PRODUCED DEATH (INCIDENCE NOT GIVEN). MICROSCOPICALLY, THE DEGREE OF CENTRAL HEPATIC NECROSIS CORRELATED WELL WITH PROLONGATION OF SLEEPING TIME (DOSE-RESPONSE DATA NOT GIVEN).
- 1,1,2-TRICHLOROETHANE: HEPATOTOXIC POTENCY WAS EVALUATED IN MICE (NUMBER, SEX, AND STRAIN NOT INDICATED) BY MEASUREMENT OF PENTOBARBITAL ANAESTHESIA (I.P. DOSE GIVEN 24 HOURS AFTER TEST COMPOUND INJECTION). NO LEVEL OF CONCERN WAS ASSIGNED TO THIS INJECTION STUDY. THE HEPATOTOXIC ED50 (TO CAUSE SLEEPING TIME INCREASE OF GREATER THAN 10 MINUTES) WAS NOT REPORTED. THE ED50 DOSE ALSO PRODUCED DEATH (INCIDENCE NOT GIVEN). MICROSCOPICALLY, THE DEGREE OF CENTRAL HEPATIC NECROSIS CORRELATED WELL WITH PROLONGATION OF SLEEPING TIME (DOSE-RESPONSE DATA NOT GIVEN).